Bloomberg

Reassessing the USPSTF mammogram recommendations

I recently had a health journalist interview me about the new guidelines for mammography under 50.

You may recall a storm of controversy was touched off in December 2009, when the US Preventive Services Task Force recommended that mammography begin at 50.  Sarah Palin went so far as to compare these recommendations to "death panels" under health care reform.  The controversy died down, and health care reform legislation was rewritten to ensure access to mammographic screening.

Study: Hormone replacement therapy increases ovarian cancer risk

Bloomberg News (7/15 Ostrow) reports Women who had hormone therapy for menopause symptoms were more likely to develop ovarian cancer regardless of the length formulation or type of treatment they received according to a study published in the Journal of the American Medical Association. The researchers noted that the finding suggests that no type of hormone seems safe regarding the risk of ovarian cancer. Furthermore if a woman has a special predisposition for ovarian cancer she should consider not taking hormones.

When A Bribe Is Not A Gift

Violating the anti-kickback statute 42 U.S.C. & 1320a-7b (b) of 1987: The statute is regulated by the Department of Health and Human Services (DHHS www.hhs.gov) and thier Office of The Inspector General (OIG) led by Daniel Levinson. Drug companies violate the False Claims Act (F.C.A.) with their marketing activities often. This can result in causing the submission of false claims in the form of prescriptions to government health care programs. The company knowingly causes to be presented to the Fed. Govt. false/fraudulent claims for payment/approval.

Syndicate content